XTL Biopharmaceuticals appoints Doron Turgeman and Shlomo Shalev to the Board of Directors
– ISRAEL – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced that the Company’s shareholders approved the appointment of two new members to the Board of Directors, Doron Turgeman and Shlomo Shalev.…
